Arsenic trioxide and acute promyelocytic leukemia: clinical and biological
- PMID: 17217042
- DOI: 10.1007/978-3-540-34594-7_8
Arsenic trioxide and acute promyelocytic leukemia: clinical and biological
Abstract
Arsenic has recently been identified as an effective drug in the treatment of newly diagnosed and relapsed acute promyelocytic leukemia. Indeed, arsenic trioxide combined with all-trans retinoic acid shows a synergistic effect. Mechanistically, arsenic targets the key leukemogenic protein PML-RARalpha, setting up a new example of molecular target-based cancer therapy.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
